Arcus Biosciences Inc
RCUS
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
189.2% downsideOvervalued by 189.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.91 Billion |
|---|---|
| Enterprise Value | $2.84 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.29 |
| Beta | 0.8 |
| Outstanding Shares | 125,400,000 |
Return
| Return on Equity | -68.89% |
|---|---|
| Return on Assets | -36.21% |
| Return on Invested Capital | -45.69% |
Valuation & Multiples
| P/E Ratio | -9.13 |
|---|---|
| PEG | -63.93 |
| Price to Sales | 28.33 |
| Price to Book Ratio | 7.08 |
| Enterprise Value to Revenue | 12.05 |
| Enterprise Value to EBIT | -7.9 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 46.12% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.10%▼ 110.77% |
|---|---|
| Total Invested | $3.91M▼ 99.85% |
| Investors Holding | 8▼ 213.00% |
ESG Score
No data
About Arcus Biosciences Inc
Relevant Senate Committees
Controls Medicare and Medicaid reimbursement and drug pricing legislation, which dictates the commercial viability of pharmaceutical products.
Determines the specific funding levels for the FDA and NIH, directly impacting the resources available for drug review and clinical research.
Directly oversees the FDA and NIH, controlling the regulatory approval process and federal research funding critical to Arcus's pipeline.
Oversees patent law and intellectual property rights, which are the fundamental value drivers for any pharmaceutical manufacturing company.